Lupin : May 25, 2023 Lupin Diagnostics Launches Satellite Laboratory in Vijayawada

Continues to Expand its Presence in South India

Vijayawada, India, May25, 2023: Global pharma major Lupin Limited (Lupin) announced today the launch of its Satellite Laboratory in Vijayawada, Andhra Pradesh. The move is part of Lupin Diagnostics' ongoing expansion aimed at enhancing access to high-quality testing services and increasing the diagnostics network across the country. The newly launched laboratory complements Lupin Diagnostics extensive network of 27 laboratories and over 410 collection centers across India. This expansion underscores Lupin's commitment to providing comprehensive diagnostic solutions and reinforcing its position in the diagnostics industry.

Lupin's new laboratory at Vijayawada is equipped with state-of-the-art diagnostic technology and staffed by a team of highly qualified clinical experts. This advanced infrastructure empowers Lupin Diagnostics to offer reliable and high-quality diagnostic services to the local community. The integration of cutting-edge technology and expertise ensures accurate and efficient testing, enabling timely diagnosis and improved patient care. In addition to routine and specialized tests, the newly launched laboratory in Vijayawada offers an extensive range of diagnostics services. These include clinical pathology, microbiology, hematology, biochemistry, serology, and immunology.

In today's healthcare landscape, evidence-based treatment has become the standard, with diagnostics tests serving as the foundation for close to 70% of treatment decisions. Lupin Diagnostics prioritizes accuracy and quality by following stringent quality control protocols. Temperature-controlled sample movement consistently ensures the integrity and quality of each sample. With a strong home collection service team and network, Lupin Diagnostics ensures patient convenience and enables tracking assigned phlebotomists, at the click of a button. The Company has also enhanced its value-added services through inclusion of dynamic smart reports for patients along with tips for monitoring their health, and historical trend graphs.

"Accurate diagnosis is the first step towards managing diseases and identifying suitable treatment," said Ravindra Kumar, CEO, Lupin Diagnostics. "With our cutting-edge technology and personalized smart reports, patients and doctors gain valuable insights into health trends, enabling informed decisions. Our mission is to make quality diagnostics affordable and accessible to everyone in India," he added.

Lupin Diagnostics is dedicated to delivering unparalleled diagnostic services to doctors, patients and consumers. Demonstrating its steadfast commitment to quality and accuracy, four of Lupin's laboratories have already attained NABL accreditation. This achievement further solidifies Lupin Diagnostics' position as a trusted leader and prioritizes excellence.

About Lupin
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.

Lupin has 15 manufacturing sites, 7 research centres, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

About Lupin Diagnostics

Lupin Diagnostics Limited is a wholly owned subsidiary of Lupin Limited. Founded in December 2021, the company is headquartered in Mumbai, India and provides comprehensive range of diagnostic services to doctors, patients, and consumers.

The company began its journey by establishing a state-of-the-art 45,000 sq. ft. National Reference Laboratory located in Navi Mumbai with world-class equipment, experienced doctors assisted by trained technologists and stringent quality control protocols. Over 2,500 tests including routine and high-end tests are offered under Pathology (molecular diagnostics, cytology, microbiology, serology, hematology, histopathology, immunology, and routine biochemistry).

Currently, the company's network consists of 27 Labs, 410+ exclusive collection centers (LupiMitra), and over 1800 pick-up points.

Experience the best diagnostic experiences with Lupin Diagnostics - https://www.lupindiagnostics.com/

Follow us on: -
Facebook: https://www.facebook.com/lupindiagnostics
Instagram: https://www.instagram.com/lupindiagnostics/
LinkedIn: https://www.linkedin.com/company/lupin-diagnostics/
Twitter: https://twitter.com/LupinDiagnostic
YouTube: https://www.youtube.com/channel/UCbj3DVAmNdbvZayKc2XCIuA

For further information or queries please contact -
Shweta Munjal
Vice President & Global Head - Corporate Communications
Email: [e-mail]

80

0